TY - JOUR T1 - Estimating the local spatio-temporal distribution of disease from routine health information systems: the case of malaria in rural Madagascar JF - medRxiv DO - 10.1101/2020.08.17.20151282 SP - 2020.08.17.20151282 AU - Elizabeth Hyde AU - Matthew H. Bonds AU - Felana A. Ihantamalala AU - Ann C. Miller AU - Laura F. Cordier AU - Benedicte Razafinjato AU - Herinjaka Andriambolamanana AU - Marius Randriamanambintsoa AU - Michele Barry AU - Jean-Claude Andrianirinarison AU - Mauricette A. Nambinisoa AU - Andres Garchitorena Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/18/2020.08.17.20151282.abstract N2 - Background Reliable surveillance systems are essential for identifying disease outbreaks and allocating resources to ensure universal access to diagnostics and treatment for endemic diseases. Yet, most countries with high disease burdens rely entirely on facility-based passive surveillance systems, which miss the vast majority of cases in rural settings with low access to health care. This is especially true for malaria, for which the World Health Organization estimates that routine surveillance detects only 14% of global cases. The goal of this study was to estimate the unobserved burden of malaria missed by routine passive surveillance in a rural district of Madagascar to produce realistic incidence estimates across space and time, less sensitive to heterogeneous health care access.Methods We use a geographically explicit dataset of the 73,022 malaria cases confirmed at health centers in the Ifanadiana District in Madagascar from 2014 to 2017. Malaria incidence was adjusted to account for underreporting due to stock-outs of rapid diagnostic tests and variable access to healthcare. A benchmark multiplier was combined with a health care utilization index obtained from statistical models of non-malaria patients. Variations to the multiplier and several strategies for pooling neighboring communities together were explored to allow for fine-tuning of the final estimates. Separate analyses were carried out for individuals of all ages and for children under five. Cross-validation criteria were developed based on overall incidence, trends in financial and geographical access to health care, and consistency with geographic distribution in a district-representative cohort. The most plausible sets of estimates were then identified based on these criteria.Results Passive surveillance was estimated to have missed about 4 in every 5 malaria cases among all individuals and 2 out of every 3 cases among children under five. Adjusted malaria estimates were less biased by differences in populations’ financial and geographic access to care. Average adjusted monthly malaria incidence was nearly four times higher during the high transmission season than during the low transmission season. Geographic distribution in the adjusted dataset revealed high transmission clusters in low elevation areas in the northeast and southeast of the district that were stable across seasons and transmission years.Conclusions Understanding local disease dynamics from routine passive surveillance data can be a key step towards achieving universal access to diagnostics and treatment. Methods presented here could be scaled-up thanks to the increasing availability of e-health disease surveillance platforms for malaria and other diseases across the developing world.Competing Interest StatementSome authors are current or former employees of institutions discussed in this article, including the non-governmental organization PIVOT and the Government of Madagascar. These affiliations are explicitly listed in the article.Funding StatementThis work was supported by internal funding from PIVOT and grants from the Agence Nationale de la Recherche (Project ANR-19-CE36-0001-01), from Institut de Recherche pour le Developpement (Project IRD Coup de Pouce MAGIE), and from the Herrnstein Family Foundation. LH was supported by the Stanford University School of Medicine Medical Scholars program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Use of MoH data for this study was authorized by the Secretary General of the Madagascar Ministry of Health, the Medical Inspector of Ifanadiana District, and Harvard Medical School IRB. The I-HOPE cohort study was approved by the Madagascar National Ethics Committee and Harvard Medical School IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be made available upon request at research{at}pivotworks.org ER -